Carcinoid tumour marker tests - chromogranin A

Role

Chromogranin A is a general marker of neuroendocrine secretory granule content, elevated across a broad range of neuroendocrine tumours (not specific to carcinoid) - used for diagnosis support, disease burden estimation, and treatment monitoring, complementing the more specific 5-HIAA test for carcinoid syndrome specifically
Widely used across neuroendocrine tumour diagnosis and follow-up given its broad applicability beyond carcinoid tumours alone (also elevated in pancreatic neuroendocrine tumours, phaeochromocytoma, and other neuroendocrine neoplasms)

Released from neuroendocrine secretory granules proportional to overall neuroendocrine cell mass/secretory activity - not specific to serotonin secretion or carcinoid tumours specifically, reflecting its broader biological role as a general neuroendocrine tumour marker rather than a syndrome-specific test

Numerous causes of false elevation reduce specificity - proton pump inhibitor use (via secondary hypergastrinaemia stimulating gastric neuroendocrine cells), renal impairment (reduced clearance), atrophic gastritis, and other conditions - these should be considered and, where possible, corrected (e.g. temporarily stopping PPI) before interpreting an elevated result as tumour-related
Levels broadly correlate with tumour burden, supporting its use in monitoring disease progression/treatment response over serial measurements
Proton pump inhibitor-associated false elevation (a frequently tested pitfall), renal impairment reducing clearance, use across multiple neuroendocrine tumour types beyond carcinoid, disease burden monitoring

Elevated chromogranin A with a compatible clinical picture supports proceeding to localisation imaging, while an isolated elevation without compatible symptoms should prompt review of confounding factors (PPI use, renal function) before extensive tumour work-up
Serial trending supports monitoring of known neuroendocrine tumour disease burden and treatment response over time

Proton pump inhibitor use is a common, clinically important cause of falsely elevated chromogranin A (via secondary hypergastrinaemia stimulating gastric neuroendocrine cell activity) - this should be actively considered, and PPI temporarily withheld where safe to do so, before interpreting an elevated result as evidence of a neuroendocrine tumour

4 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.